Sugi Predict

Sugi Predict / Compounds / SCHEMBL1946136

SCHEMBL1946136

SCHEMBL1946136

COc1ccc(-c2cnc3sc(NCC(C)C)nn23)cc1OC

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ FYN P06241 18/20 1.00
▸ MKNK1 Q9BUB5 1/20 0.67
▸ PIK3CA P42336 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1944676 0.89 FYN (0.80) FYNMKNK1
SCHEMBL2255543 0.85 FYN (0.74) FYNPIK3CA
SCHEMBL27794654 0.84 FYN (0.73) FYNPIK3CA
SCHEMBL1943613 0.84 FYN (0.72) FYNPIK3CA
SCHEMBL1945974 0.83 FYN (0.71) FYNMKNK1
SCHEMBL1943655 0.82 FYN (0.70) FYNPIK3CA
SCHEMBL1650487 0.82 FYN (0.82) FYN
SCHEMBL1946739 0.82 FYN (0.86) FYNMKNK1PIK3CA
SCHEMBL1945313 0.81 FYN (0.83) FYN
SCHEMBL1943706 0.81 FYN (1.00) FYNMKNK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180250297-A1 Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors Pathways Neuro Pharma, Inc. 2018-09-06 — — US claimed
EP-3347462-A1 METHODS, COMPOSITIONS, AND USES OF NOVEL FYN KINASE INHIBITORS Lau, Warren C. (US) 2018-07-18 — — EP claimed
WO-2017044623-A1 METHODS, COMPOSITIONS, AND USES OF NOVEL FYN KINASE INHIBITORS LAU WARREN C (US) 2017-03-16 — — WO claimed
EP-2307425-B1 IMIDAZOTHIADIAZOLES DERIVATIVES MERCK PATENT GMBH (DE) 2014-03-26 — — EP claimed
US-20240041868-A1 Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors Pathways Neuro Pharma, Inc. 2024-02-08 — — US disclosed
US-11701353-B2 Methods, compositions, and uses of novel FYN kinase inhibitors Pathways Neuro Pharma, Inc. (US) 2023-07-18 — — US disclosed
US-11701353-B2 Methods, compositions, and uses of novel FYN kinase inhibitors Pathways Neuro Pharma, Inc. (US) 2023-07-18 — — US disclosed
US-11701353-B2 Methods, compositions, and uses of novel FYN kinase inhibitors Pathways Neuro Pharma, Inc. (US) 2023-07-18 — — US disclosed
US-20210030753-A1 Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors Pathways Neuro Pharma, Inc. 2021-02-04 — — US disclosed
US-10688093-B2 Methods, compositions, and uses of novel Fyn kinase inhibitors Pathways Neuro Pharma, Inc. 2020-06-23 — — US disclosed
EP-2193133-B1 IMIDAZOLOTHIADIAZOLES FOR USE AS PROTEIN KINASE INHIBITORS FUNDACIÓN CT NAC DE INVESTIGACIONES ONCOLÓGICAS CARLOS III (ES) 2015-08-19 — — EP disclosed
CN-101878219-B Imidazothiadiazoles for use as protein kinase inhibitors CT NAC DE INVESTIGACIONES ONCO 2014-04-02 — — CN disclosed
US-8389554-B2 Imidazothiadiazole derivatives MERCK Patent Gesellschaft mit beschränkter Haftung (DE) 2013-03-05 — — US disclosed
US-20110190289-A1 Imidazolothiadiazoles for Use as Protein Kinase Inhibitors CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) 2011-08-04 — — US disclosed
US-20110130396-A1 IMIDAZOTHIADIAZOLE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2011-06-02 — — US disclosed
US-20110130396-A1 IMIDAZOTHIADIAZOLE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2011-06-02 — — US disclosed
US-20110130396-A1 IMIDAZOTHIADIAZOLE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2011-06-02 — — US disclosed
CN-101878219-A Imidazothiadiazoles for use as protein kinase inhibitors CT NAC DE INVESTIGACIONES ONCO 2010-11-03 — — CN disclosed
EP-2193133-A2 IMIDAZOLOTHIADIAZOLES FOR USE AS PROTEIN KINASE INHIBITORS Centro Nacional de Investigaciones Oncológicas (CNIO) (ES) 2010-06-09 — — EP disclosed
WO-2009040552-A2 SUBSTITUTED IMIDAZO (2, 1-B) -1, 3, 4-THIAZOLE COMPOUNDS, THEIR PHARMACEUTICAL COMPOSITIONS AND USES THEREOF CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) 2009-04-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240041868-A1 Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors FYN, LCK, PTK2B FYN 1/4885MKNK1 163/4885PIK3CA 227/4885
US-20110190289-A1 Imidazolothiadiazoles for Use as Protein Kinase Inhibitors PIM1, PIM3, PIM2 FYN 383/4885MKNK1 147/4885PIK3CA 150/4885
US-20180250297-A1 Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors FYN, LCK, PTK2B FYN 1/4885MKNK1 163/4885PIK3CA 227/4885
US-11701353-B2 Methods, compositions, and uses of novel FYN kinase inhibitors FYN, LCK, PTK2B FYN 1/4885MKNK1 163/4885PIK3CA 227/4885
US-20110130396-A1 IMIDAZOTHIADIAZOLE DERIVATIVES TGFBR1, TGFBR2, IGF1R FYN 1977/4885MKNK1 860/4885PIK3CA 1012/4885
US-10688093-B2 Methods, compositions, and uses of novel Fyn kinase inhibitors FYN, LCK, PTK2B FYN 1/4885MKNK1 163/4885PIK3CA 227/4885
US-20210030753-A1 Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors FYN, LCK, PTK2B FYN 1/4885MKNK1 163/4885PIK3CA 227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.